Ranatuerin-2PLx (1-22), R2PLx (1-22)

General Information


DRACP ID  DRACP03749

Peptide Name   Ranatuerin-2PLx (1-22), R2PLx (1-22)

Sequence  GIMDTVKNAAKNLAGQLLDKLK

Sequence Length  22

UniProt ID  Not available

PubChem CID  Not available

Origin  Synthetic

Type  Synthetic peptide

Classification

  

Active ACP



Activity Information


Hemolytic Activity  Not available

Normal (non-cancerous) Cytotoxicity  Not available

Target  Not available

Affinity  Not available

Mechanism  Not available

Nature  Anticancer; Antibacterial; Antifungal



Structure Information


PDB ID  Not available

Predicted Structure  Not available

Helicity  Not available

Linear/Cyclic  Linear

Disulfide/Other Bond  Not available

N-terminal Modification  Free

C-terminal Modification  Free

Other Modification  None

Chiral  L



Physicochemical Information


Formula  C102H181N29O31S

Absent amino acids  CEFHPRSWY

Common amino acids  KL

Mass  271659

Pl  10.33

Basic residues  4

Acidic residues  2

Hydrophobic residues  9

Net charge  2

Boman Index  -2273

Hydrophobicity  -15.45

Aliphatic Index  115.45

Half Life 
  Mammalian: 30 hour
  Yeast: >20 hour
  E.coli: >10 hour

Extinction Coefficient cystines  0

Absorbance 280nm  0

Polar residues  5

Amino acid distribution



Literature Information


Literature 1

Pubmed ID 30279210

Title  A novel antimicrobial peptide, Ranatuerin-2PLx, showing therapeutic potential in inhibiting proliferation of cancer cells

Doi Not available

Year  2018

Patent

Patent ID Not available

Patent Title  Not available

Other Iinformation  Not available

Other Published ID  Not available




DBAASP ID  12185

DRACP is developed by Dr.Zheng's team.